Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Swiss Med-tech hotspot – Wednesday, 24th September 2014 SWISS MED-TECH HOT-SPOT – OPENING UP YOUR BUSINESS HORIZONS OFFICIAL PROGRAM Introduction Many investors recognise Europe as an attractive and transparent market where innovative companies wish to expand and invest. Switzerland is undoubtedly one of the best-known European Med-tech hotspots where companies benefit from a central European geographical location, an excellent infrastructure, highly skilled human capital and an excellent R&D capacity. Many Swiss Med-tech companies have their own R&D Units and this creates a vibrant environment within the sector. Med-tech product development requires precision, technical expertise and complex knowledge, demanding interaction from different fields and professionals such as engineers, doctors, scientists and IT experts. Switzerland has an extremely highly skilled workforce, capable of achieving such synergies among these areas. Switzerland has become a prominent centre for several industry clusters, including Life Sciences, pharmaceuticals and medical technology. A range of players are present, from producers, suppliers and research institutes to third party service providers. Investors will benefit from this vibrant environment, allowing companies to prosper in terms of spinout as well as possible business synergies. Reasons to consider Switzerland the leading Med-tech hotspot and to attend this event: Switzerland hosts the most attractive companies in the field such as Novartis Pharma, Synthes, Roche Diagnostics, Sonova, Ypsomed and Straumann, Johnson & Johnson, Zimmer, Medtronic, B. Braun and Stryker amongst many others. Switzerland has a vast chain of suppliers in the Med-tech industry, who are highly specialized. Total Med-tech turnover was estimated at CHF 12.5bn in 2011, which is equivalent to 2.1% of Swiss GDP. This represents the highest share in the leading European medtech regions (UK: 0.4% of GDP and Germany: 0.8%). R&D is crucial for innovation. In Switzerland, Med-tech manufacturers spend 13% of their turnover on R&D and suppliers 8%. The Swiss Med-tech market spends approximately CHF 1.4bn on R&D. The Swiss Med-tech market has the highest density of patent applications within Europe. The Med-tech market is worth approximately CHF 7.2bn, which represents 11% of Swiss healthcare expenses. The industry experienced growth of 10% in 2010. In the vibrant environment of the Swiss Med-tech industry, collaboration, quality and consistency are key success factors. Switzerland has strong Life Science clusters with the presence of a large number of global domestic companies headquartered in its territory, as well as non-domestic companies. The Life Science workforce represents a high percentage, considering the total active population. ConCep+ Think Tank & Strategy Consultant Event Programme th Wednesday 24 September 2014 5.30pm Registration and Reception 6:00pm Welcome address by Ambassador Dominik Furgler Presentation and Networking: 6.05pm Why Switzerland is an attractive Market Switzerland as an attractive Market Ambassador of Switzerland to the United Kingdom, HE Dr Dominik Furgler 6.20pm Switzerland as the leading Med-tech hotspot in Europe Dr Patrick Dümmler, Partner, Concept+ 6.40pm Biotechnology and Life Science in Switzerland Dr Lutz-Peter Berg, Science & Technology Attaché, Embassy of Switzerland 7.00pm Testimonial Mr Paul Cowan, Chairman & Chief Executive Officer Quotient Limited 7.20pm Break 7.30pm Dinner 9.00pm Carriages Contact Ms Veronica Castel-Branco, Senior Investment Officer Swiss Business Hub United Kingdom DDI: +44 (0)20 7616 6050 Email [email protected] RSVP by th Monday, 5 September 2014 Invitations are strictly personal and non-transferable